The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1836-1843

  McFarlane, Cheryl ^a   McFarlane, Suzanne ^a   Paul, Ian ^a   Arthur, Kenneth ^a   Scheaff, Michael ^b   Kerr, Keith ^c   Stevenson, Michael ^a   Fennell, Dean A ^a,d   Johnston, James A ^a,e  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e AMGEN INC   (United States)

Author keywords

Deubiquitination; Metastasis; NSCLC; Ubiquitination; USP17

Indexed keywords

PROTEINASE; TUMOR MARKER; UBIQUITIN SPECIFIC PROTEASE 17; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOPEPTIDASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UBIQUITINATION;

EID: 84886741837     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1282     Document Type: Article

References (33)

1. Nakayama KI, Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6:369-381.
2. Sippl W, Collura V, Colland F: Ubiquitin-specific proteases as cancer drug targets. Future Oncol 2011, 7:619-632.
3. Sacco JJ, Coulson JM, Clague MJ, Urbe S: Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life 2010, 62:140-157.
4. Clague MJ, Coulson JM, Urbe S: Cellular functions of the DUBs. J Cell Sci 2012, 125:277-286.
5. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C: Deubiquitinases in cancer: new functions and therapeutic options. Oncogene 2012, 31:2373-2388.
6. Komander D, Clague MJ, Urbe S: Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009, 10:550-563.
7. Brooks CL, Li M, Hu M, Shi Y, Gu W: The p53--Mdm2--HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene 2007, 26:7262-7266.
8. Masuya D, Huang C, Liu D, Nakashima T, Yokomise H, Ueno M, Nakashima N, Sumitomo S: The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol 2006, 208:724-732.
9. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, Pandolfi PP: The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008, 455:813-817.
10. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M: The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 2004, 5:253-261.
11. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M: The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res 2006, 66:8625-8632.
12. da Silva SD, Cunha IW, Nishimoto IN, Soares FA, Carraro DM, Kowalski LP, Graner E: Clinicopathological significance of ubiquitin-specific protease 2a (USP2a), fatty acid synthase (FASN), and ErbB2 expression in oral squamous cell carcinomas. Oral Oncol 2009, 45:e134-9.
13. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 2010, 140:384-396.
14. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M: The ubiquitinspecific protease USP28 is required for MYC stability. Nat Cell Biol 2007, 9:765-774.
15. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, Viale G, Di Fiore PP, Confalonieri S: An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011, 6:e15891.
16. Reyes-Turcu FE, Ventii KH, Wilkinson KD: Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397.
17. Burrows JF, McGrattan MJ, Johnston JA: The DUB/USP17 deubiquitinating enzymes, a multigene family within a tandemly repeated sequence. Genomics 2005, 85:524-529.
18. Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, Govender U, Quinn DJ, Dib K, Gadina M, Scott CJ, Johnston JA: USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem 2009, 284:9587-9595.
19. de la Vega M, Burrows JF, McFarlane C, Govender U, Scott CJ, Johnston JA: The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected. J Biol Chem 2010, 285:12028-12036.
20. McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF, Johnston JA: The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res 2010, 70:3329-3339.
21. de la Vega M, Kelvin AA, Dunican DJ, McFarlane C, Burrows JF, Jaworski J, Stevenson NJ, Dib K, Rappoport JZ, Scott CJ, Long A, Johnston JA: The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. Nat Commun 2011, 2:259.
22. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M: The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008, 3:1468-1481.
23. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A, Hallett M, Park M: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008, 14:518-527.
24. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F: EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005, 23:857-865.
25. O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB, Vachani A: Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012, 3:414-425.
26. Colland F: The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010, 38:137-143.
27. Moiseeva TN, Bottrill A, Melino G, Barlev NA: DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity. Oncotarget 2013.
28. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J, Calabrese A, Borg-Capra C, Sippl W, Collura V, Boissy G, Rain JC, Guedat P, Delansorne R, Daviet L: Smallmolecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009, 8:2286-2295.
29. Cohen P, Tcherpakov M: Will the ubiquitin system furnish as many drug targets as protein kinases? Cell 2010, 143:686-693.
30. Mok TS: Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011, 8:661-668.
31. Dienstmann R, Martinez P, Felip E: Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011, 2:165-177.
32. Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA: PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J Pathol 2011, 224:564-574.
33. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168.